34 / 43
0
5
10
15
20
25
30
35
40
45
Overall
≤6 >6–≤12 >12–≤18 >18–≤24 >24–≤30 >30–≤36
>36
Months
Events/Patients at Risk (%)
Emergence of Select Treatment-Related
AEs (Any Grade) Over Time
No. of patients at risk
Minimum follow-up: 50.5 months (CA209-003) and 49.2 months (CA209-010); reported as of June 2016.
AE, adverse event.
Included with permission from McDermott DF et al. Oral presentation at ASCO 2016. 4507.
•
Select treatment-related AEs included endocrine, gastrointestinal, hepatic,
pulmonary, renal, and skin
CA209-010: monotherapy